IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)

Utilizing the immune system or components thereof has grown to be a powerful therapeutic option in cancer, supplementing
traditional therapies such as surgery, radiotherapy and chemotherapy. However, not all patients respond equally well to
immune-based therapies, highlighting the need for improving immunotherapy outcome. The INTEGRAL IOF programme aims
to reinforce the complementary offering of expertise, know-how, knowledge and technologies originating from 3 VUB
laboratories (In vivo Cellular and Molecular Imaging; Cellular and Molecular Immunology; Molecular and Cellular Therapy), to
address this issue, by offering tools for combining immune activation (ACTIVATION) with negating immunosuppressive cues
(MODULATION), steering drug development (MODE OF ACTION analysis) and driving patient selection and monitoring of
therapy response (via in vivo IMAGING). By acquisition of a new state-of-the-art protein purification device we will accelerate
reaching these ambitious goals shared by the three research laboratories.